Article thumbnail
Location of Repository

Cytokine and Chemokine protein levels in the SNpc following Nurr1 agonist treatment.

By Gaynor A. Smith (713611), Emily M. Rocha (713612), Thomas Rooney (5662747), Pascal Barneoud (713613), Jesse R. McLean (713614), Jonathan Beagan (713615), Teresia Osborn (713616), Madeleine Coimbra (713617), Yongyi Luo (713618), Penelope J. Hallett (713619) and Ole Isacson (44911)


<p><sup>a</sup> Cytokines and chemokine levels in the SN (pg/mg), analyzed by multiplex ELISA</p><p><sup>b</sup> Data is represented as mean ± SEM and significance is annotated as *p<0.05</p><p>Cytokine and Chemokine protein levels in the SNpc following Nurr1 agonist treatment.</p

Topics: Biological Sciences, Nurr 1 agonist treatment causes neuroprotective, dat, microglial morphology, proinflammatory cytokines, snpc, vmat, substantia nigra pars compacta, dopamine neuron degeneration model, novel Nurr 1 agonist, Nurr 1, dopamine synthesis, inflammation, pd, Daily gavage treatment, neuroprotective effects, il, OHDA, GFAP staining intensity, dopaminergic neurons, Nurr 1 expression, aadc, dopaminergic target genes, SA 00025, 32 days, sn, iba, Nurr 1 Agonist Causes Neuroprotection, dopaminergic neuron degeneration, dopaminergic phenotype genes TH, staining intensity, gdnf
Year: 2015
DOI identifier: 10.1371/journal.pone.0121072.t001
OAI identifier:
Provided by: FigShare
Download PDF:
Sorry, we are unable to provide the full text but you may find it at the following location(s):
  • (external link)
  • Suggested articles

    To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.